Copper Supplementation in Cirrhosis
A legfontosabb adatok
- Ki végzi
- University of Washington
- Hol
- Seattle (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 30 fő, tervezett
- Kezdés
- 2026. márc. 15.
- Várható befejezés
- 2028. dec.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- Copper Gluconate
- A regiszteradat frissítve
- 2026. március 13.
Ki vehet részt
The trial is looking for adults with cirrhosis (severe liver scarring) who have low copper in the blood, or normal copper with signs linked to low copper. It tests copper supplements against a placebo (dummy pill).
- Életkor
- 18 years or older
- Nem
- All sexes
- A betegség stádiuma
- Confirmed cirrhosis. People with a MELD score (a liver disease severity score) above 25 cannot join.
- Biomarker vagy leletérték
- Blood copper below normal (80-155 ug/dL for women, 70-140 ug/dL for men). Or normal copper plus at least one sign linked to low copper: past infections, unexplained anemia, severe leukopenia (very low white blood cells), iron overload, unexplained nerve symptoms such as ataxia or myelopathy, or clotting problems with spontaneous bleeding.
- A részvétel fő kizáró okai
- Wilson disease, primary biliary cholangitis or primary sclerosing cholangitis
- Sudden severe liver failure (fulminant hepatic failure), or hepatic encephalopathy (brain problems from liver disease) more than grade 2
- Kidney failure with creatinine clearance <25 ml/minute
- Serious illness not related to the liver, such as heart, lung or kidney disease or cancer outside the liver
- Current alcohol use, or pregnancy
A regiszter összes feltétele (11)A regiszter feltételeinek elrejtése
Ki vehet részt
- Adult patients age 18 or older with confirmed diagnosis of cirrhosis based on clinical history, exam, imaging, laboratory or histological criteria
- Cirrhosis patients whose serum or plasma Cu are below the normal range (80-155 ug/dL for women and 70-140 ug/dL for men)
- Cirrhosis patients whose serum or plasma Cu are in the normal range but exhibit at least one clinical feature that has been associated with Cu deficiency. These include history of infections, unexplained anemia, severe leukopenia, iron overload, unexplained neurological symptoms such as ataxia or myelopathy, coagulopathy with spontaneous bleeding; Patients must meet inclusion criteria 1 AND 2, or 1 AND 3 in order to be considered for the trial
Ki nem vehet részt
- Patients with Wilson disease, cholestatic liver diseases including primary biliary cholangitis and primary sclerosing cholangitis, all of which are associated with Cu overload
- Patients with fulminant hepatic failure
- Hepatic encephalopathy more than grade 2 (Hepatic Encephalopathy in Chronic Liver Disease, 2014)
- Serious non-liver related medical illnesses such as cardiopulmonary and renal diseases and non-liver malignancies
- Renal failure with a creatinine clearance <25 ml/minute
- MELD score >25 to minimize subject dropout due to been too ill
- Active alcohol use
- Pregnancy
Alkalmassági kérdőív
Ez nem döntés: hogy ki vehet részt, azt csak a vizsgálat csapata mondhatja meg.
- Életkor
Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.
- University of Washington Medical CenterSeattle, Egyesült ÁllamokContact: Shukriyah Samoun, BSRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
End stage liver disease or cirrhosis is a major cause of mortality in the United States and the world. Other than targeting the underlying cause, such as alcohol cessation and antiviral therapy, very few medical treatments can change the natural history of cirrhosis. Malnutrition is one of the few potentially modifiable factors that have been associated with cirrhosis severity and poor prognosis. The transition metal copper (Cu) is an essential trace metal that must be acquired from diet. Its metabolism is primarily regulated by the liver in its role as a master regulator of nutrients. In 2019, the investigators reported that Cu deficiency defined by below normal serum or liver concentrations occurred in a wide range of liver disorders and was associated with a severe disease phenotype. Improvement in liver function was observed in 2 of the 3 patients who received Cu supplementation. In 2023, the investigators conducted a longitudinal cohort study utilizing clinical, serum and liver explant tissue data from 183 cirrhosis patients. The investigators showed that Cu deficiency was associated with 2-fold higher infection rate and a more than 3-fold increase in the risk of death compared to patients with normal Cu status. These preliminary findings and the well-established importance of Cu in human health prompted the investigators to design the current pilot randomized, placebo-controlled, crossover trial to determine the effect of Cu supplementation on Cu dependent biochemical changes, patient safety and patient reported outcomes in cirrhosis.
A vizsgálat 2 csoportja
- Copper supplementation 1st armA vizsgált kezelés
copper supplementation first, washout, then placebo
Kezelés: Copper Gluconate
- Placebo first armA vizsgált kezelés
Placebo first, washout, then copper supplementation
Kezelés: Copper Gluconate
Következő lépések
Az orvosodnak
Kérdőlap az orvosnak
PDF az orvosodnak: mit vizsgál a vizsgálat, ki vehet részt, és 1 kérdés a részvételi feltételekről, hellyel a válaszoknak és a jegyzeteknek.
PDF, US Letter, 1–2 oldal. A4 méretben
A vizsgálati csapatnak
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Pilot Randomized Controlled Trial to Determine the Biochemical Effect, Safety and Patient Reported Outcomes of Copper Supplementation in Patients With Cirrhosis
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT07471542: ki vehet részt
- A regiszteradat frissítve
- 2026. március 13.